Insider buying last 90 days
No open-market insider purchases were filed for JANX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every JANX insider filing, plotted on the chart in Gekko.Open JANX in Gekko
NASDAQ: JANX
Janux Therapeutics (JANX) Stock Analysis & Forecast
Oct 12 close
$18.15−0.24 (−1.3%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on a head-to-head comparison between Janux Therapeutics and Roivant Sciences, weighing the two healthcare companies on earnings, risk, dividends, analyst recommendations, profitability and institutional backing. No company-specific results, guidance, deal or regulatory update accompanies the comparison.
JANX closed at $18.15, down 1.3% on the day, with the close sitting above both the 50-day average of $17.38 and the 200-day average of $15.10, and the 50-day above the 200-day. The GekkoIndex reads 51.7, placing the stock in the Neutral zone, down from a five-day change of -10.3. Shares trade 25.3% below Gekko Fair Value of $24.29. Over the past year the stock is down 29.8%, though the 1-month, 3-month and 6-month returns are all positive at 6.1%, 15% and 21.8% respectively.
The next 20 trading days bring the earnings date of 5 November 2026, 24 days away, which falls inside that window; the prior report on 6 August 2026 produced a reaction of -0.9% against an average absolute move of 2.2%, with 5 beats across 8 quarters. No insider, Congress or unusual options activity is recorded in their respective windows, though one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged a 8.8% return over 5 years, rising in 3 of them. Analyst coverage includes 10 buy ratings, 1 sell, and a consensus target of $36.24.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Janux Therapeutics price vs fair value
Close $18.15200-day averageGekko Fair Value $24.29
Janux Therapeutics quick facts
- Market cap
- $1.11B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.64
- Revenue, TTM
- $24.00M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.39
- Volume
- 802,987 avg 968,647
- 1-year return
- −29.8%
- Typical daily move
- ±5%
- Typical 20-day move
- ±13.3%
- 50-day average
- $17.38
- 200-day average
- $15.10
- Next earnings
- Nov 5
- Shares outstanding
- 61.14M
Janux Therapeutics swing-trade checklist
Janux Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $18.15 is above the 50-day ($17.38) and 200-day ($15.10) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.7, Neutral
Reading 51.7 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
25.3% below
Price is 25.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+8.8% on average
From this point in the calendar, the next 20 trading days averaged +8.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Janux Therapeutics stock chart and price history
Janux Therapeutics closed at $18.15 on Oct 12, 2026, −29.8% over the past year, inside a 52-week range of $12.12 to $35.34.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.1%
- 3 months
- +15.0%
- 6 months
- +21.8%
- 1 year
- −29.8%
The full JANX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open JANX in Gekko
Follow Janux Therapeutics through every session
Put JANX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track JANX in GekkoFree for 7 days. No credit card required.
Janux Therapeutics GekkoIndex: the smart money zone
Janux Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.7, in the Neutral zone, down 10.3 points over five sessions.
51.7Neutral
Down 10.3 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +3.1% | +29.0% | ||
| Accumulation | 279 | +0.9% | +14.8% | ||
| Neutral (current zone) | 327 | +1.7% | +3.1% | ||
| Distribution | 31 | −2.5% | −9.3% | ||
| Selling | 8 | Too few readings yet | |||
Average JANX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the JANX price, zone by zone.Track JANX in Gekko
Is Janux Therapeutics stock overvalued? Gekko Fair Value
Janux Therapeutics trades 25.3% below Gekko Fair Value of $24.29, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Janux Therapeutics shares are worth, recalculated every trading day.
$24.29
Gekko Fair Value, Oct 10, 2026
25.3% Undervalued
At the end of Aug 2026 the price was 37.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open JANX in Gekko
Janux Therapeutics insider and Congress trading
No open-market insider purchases were filed for Janux Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in JANX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for JANX, plotted on the chart in Gekko.Open JANX in Gekko
Buybacks
Janux Therapeutics has been buying back its own shares.
- Bought back, year ended Dec 31, 2025
- $347K
- As a share of market cap
- 0.03%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds JANX.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Janux Therapeutics earnings: next date and track record
Janux Therapeutics reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.47
- Revenue estimate
- $8.03M
5 of 8reports beat the EPS estimate
±2.2%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.35 est −$0.25 | $10.27M est $19.07M | −0.9% |
| May 7, 2026 | −$0.39 est −$0.52 | $3.73M est $4.36M | −3.0% |
| Feb 26, 2026 | −$0.51 est −$0.65 | $7.88M est $83K | −0.7% |
| Nov 6, 2025 | −$0.39 est −$0.60 | $10.00M | −3.8% |
| Aug 7, 2025 | −$0.55 est −$0.48 | — est $300K | −5.6% |
| May 8, 2025 | −$0.38 est −$0.43 | — est $660K | −0.5% |
| Feb 27, 2025 | −$0.36 est −$0.49 | — est $1.82M | +0.9% |
| Nov 6, 2024 | −$0.51 est −$0.37 | $439K est $1.50M | −1.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Janux Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Janux Therapeutics is $36.24, +99.7% from the last close, from 11 firms rating the stock in the last 90 days.
$36.24consensus 12-month target, +99.7% from the last close
Now $18.15Avg $36.24
Low $14High $60
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | H.C. Wainwright | $45 | +147.9% |
| Aug 24 | Wolfe Research | $23 | +26.7% |
| Aug 13 | William Blair | — | — |
| Aug 11 | Stifel Nicolaus | $35 | +92.8% |
| Aug 10 | H.C. Wainwright | $45 | +147.9% |
+3.1%average 20-day move after past Neutral readings
+8.8%average move over the next 20 trading days in the last 5 years
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Janux Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Janux Therapeutics averaged +8.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.2% | 4 of 5 |
| Next 10 trading days | +4.1% | 3 of 5 |
| Next 15 trading days | +12.7% | 4 of 5 |
| Next 20 trading days | +8.8% | 3 of 5 |
| Next 30 trading days | +1.9% | 3 of 5 |
For scale, JANX’s typical 20-trading-day move in either direction is about 13.3%.
Janux Therapeutics market cap and key statistics
Janux Therapeutics’s market cap is $1.11B and revenue of $24.00M over the last twelve months.
Valuation
- Market cap
- $1.11B
- EPS, TTM
- −$1.64
- Gekko Fair Value
- $24.29
Trading
- Volume
- 802,987
- Avg volume, 20 days
- 968,647
- 52-week high
- $35.34
- 52-week low
- $12.12
- Shares outstanding
- 61.14M
Financials
- Revenue, TTM
- $24.00M
- Profit margin
- 0%
- Return on equity
- -10.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.39
- Typical daily move
- ±5%
- Typical 20-day move
- ±13.3%
Janux Therapeutics stock news this week
1 headline about Janux Therapeutics from the past week, newest first, each linking to the publisher.
Janux Therapeutics peers
Janux Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Janux Therapeutics stock FAQ
What is Janux Therapeutics’s market cap?
Janux Therapeutics’s market cap is $1.11B at the Oct 12, 2026 close of $18.15, with 61.14M shares outstanding.
What is the Janux Therapeutics stock forecast?
The consensus analyst 12-month price target for Janux Therapeutics is $36.24, +99.7% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Janux Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Janux Therapeutics is undervalued: the Oct 12, 2026 close of $18.15 is 25.3% below Gekko Fair Value of $24.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Janux Therapeutics report earnings next?
Janux Therapeutics is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.47 per share on revenue of $8.03M. Janux Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 2.2% on average across the report.
What is Janux Therapeutics’s 52-week high and low?
Janux Therapeutics’s 52-week high is $35.34 and its 52-week low is $12.12; it closed at $18.15 on Oct 12, 2026, −29.8% over the past year. Over the last five years the shares peaked at $71.71 on Dec 5, 2024.
Is Janux Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Janux Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.